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Of 114PICCs analyzed in 106 children, median age was 7.5years (range 1-
18yrs); haematological malignancies constituted 78.3% (83/106).The me-
dian catheter life was 155.5days with a total of 17,941 catheter day-
s.Elective removal was done in 57% (65/114).Another 34 (29.8%).patients
are currently on therapy.Five patients (4.4%) were lost to follow up.Inci-
dence of AE was 0.725 per 1,000 catheter days. Removal due to AE was
required in 8.8% (10/114). AE included suspected infection (5/13), docu-
mented line infection (3/13; gram negative¼2, gram positive ¼1), acci-
dental extrusion (2/13), exit site skin necrosis (3/13) with AE incidence of
0.279, 0.167, 0.111 and 0.167per 1000 catheter days respectively.
Among 30 surgically implanted CVADs in 30 children, themedian agewas 6
years (10monthse 18 years).Solid tumors, hematological malignancies and
benign haematological diseases constituted 66.6% (20/30),16.7% (5/30)
and16.7% (5/30) respectively. All Hickman catheters were inserted in pa-
tients undergoing bone marrow transplant. Median CVAD life was 147 days
with a total of 4983 CVAD days. Elective removal was done in 26.6% (8/30),
treatment is ongoing in 56.6% (17/30).AE rate was 1.204 per 1,000 catheter
days (6/30) which included catheter tip migration in a left IJV chemoport
managed without removal. Reasons for catheter removal were suspected
infection (3/5), tunnel track infection in Hickman (1/5) and partial port
extrusion (1/5) with AE rates of 0.602,0.201 and 0.201per 1000 catheter
days respectively.None of the catheter tip cultures yielded any organisms.
Age, diagnosis and type of catheter were not statistically signiﬁcant but
number of catheter days was a statistically signiﬁcant predictor of AE
(P¼0.0063).
Conclusion: CVADs are a safe and a reliable method of securing vascular
access in children with malignancies.Tunnelled catheters have more
complications compared to PICC albeit with an acceptable and manage-
able incidence.TM_SC-1_V1.13
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Objectives: Pattern of respiratory viral infections (RVI) in children with
cancers is not well characterized in India. We conducted this study to
determine the spectrum, incidence of fever-neutropenia, need for hospital
admission, economic burden, and outcome (concomitant bacterial in-
fections, need for ICU care, and death) of RVI in our pediatric-oncology
unit.
Methods: Data was collected retrospectively from July 2015-April 2016. All
children (<18-years) with symptoms of an upper respiratory tract infec-
tion (fever/cough/rhinorrhea) were included. Nasal and throat swabs were
collected in Hi-Viral transport medium and analyzed using duplex Real
Time PCR with Taqman Probes-Vi. Children with Inﬂuenza A/B received
oseltamivir; those with symptomatic Respiratory Syncitial Virus (RSV)
received ribavirin. All children with fever-neutropenia received intrave-
nous antibiotics as per unit protocol.
Results: 104 viral isolates were identiﬁed in 89 patients. Median age was
5.5-years (range: 1.4-17.8); 65% were males. Majority of the episodes (91%)
were in haemato-lymphoid malignancies. For children on treatment for
ALL, 35 (42%) were in intensive and 48 (58%) in non-intensive phase of
chemotherapy. Clinical features included: fever (89.5%), cough (71%), rhi-
norrhea (25%), chest-signs (25%), vomiting (12.5%), diarrhea (5.5%), rash
(2%). Commonest isolate was Inﬂuenza-A (36.5%) followed by RSV (22.1%),
Coronavirus (9.6%), Metapneumovirus (8.7%), Parainﬂuenza (8.7%), Inﬂu-
enza-B (6.7%), Adenovirus (1.9%) and Rhinovirus (1.9%). Multiple viruses
were found in 4 (3.8%). Hematological parameters at presentation
included: hemoglobin (median:9.9g%, IQR 8.7;11.1), platelet (me-
dian:1,41,605/mm3, IQR 60,000;1,95,750), neutrophil count (median:1962/
mm3; IQR 390;2446), lymphocyte count (median:1277/mm3, IQR
300;1155), Neutrophil:lymphocyte ratio (NLR) (median:3.5; IQR0.3-4.2).
Overall, 50% of episodes warranted admission; majority (88.5%) with fever-
neutropenia. Concomitant bacterial infection was documented in 11(10.5%) episodes, with Pseudomonas (5;45%) being the commonest isolate.
One died (0.9%) following Acinetobacter sepsis with RSV infection. Twenty-
ﬁve (54%) required empirical escalation of antibiotics due to persistent
fever-neutropenia; 7 (28%) had a proven bacterial isolate. Six/104 (5.7%)
children needed ICU admission; 5 (83%) had concomitant bacteremia
(p<0.001).Median duration of neutropenia was 12-days (range:1-47).
Median duration of hospital-stay was 8-days (range:1-35).Median cost of
admission was INR 22,466 (range:2,176-1,15,160).Cost and duration of stay
was signiﬁcantly more in children with concomitant bacteremia
(p¼0.002). Median cost for children with RVI and no bacteremia, whose
antibiotics were escalated empirically (median INR 60,217, IQR 41,131;
1,24,037), was signiﬁcantly higher than those who stayed on 1st-line an-
tibiotics (median INR 11,503, IQR 2,699;24,868) (p<0.001).
On univariate analysis, signiﬁcant predictor of bacteremia in RVI was low
hemoglobin (p¼0.01). Median hemoglobin in children with bacteremia
(8.4g%, IQR 6.6;9.8) was signiﬁcantly lower than those without bacteremia
(10g%; IQR 9;11.3; p¼0.06). Age (p¼0.8), gender (p¼0.5), underlying ma-
lignancy (p¼0.6), intensive chemotherapy (p¼0.1), neutrophil count
(p¼0.1), duration of neutropenia (p¼0.72), lymphocyte count (p¼0.9),
platelet count (p¼0.1) and NLR (p¼0.1), failed to predict bacteremia.
Conclusion: Documented RVI in children with cancers does not preclude
bacteremia. However, cost of care gets signiﬁcantly increased for children
with RVI and persistent fever-neutropenia, evenwith no bacteremia, when
empirically escalated to higher antibiotics as per protocol (p<0.001). A
prospective study is needed to analyze whether the protocol for antibiotic-
escalation can be better rationalized in this cohort.
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Introduction: Reavan in 1988 noted that several risk factors for car-
diovascular diseases commonly cluster together, and he recognised
them as a disease, named syndrome X, currently known as metabolic
syndrome.Metabolic syndrome is a group of disorders related to insulin
resistance, characterized clinically by central obesity, hyperglycemia,
dyslipidemia and hypertension. There is a growing body of evidence
indicating that pediatric cancer survivors are at a greater risk of
developing metabolic syndrome. We studied the prevalence of meta-
bolic syndrome in children with cancer who completed their treatment
and on follow up.
Methodology: All relevant past medical data (of the disease, treatment
and all events) were collected from the medical records.Tanner staging
was perfomred, Height was measured using a Harpenden stadiometer.
Weight/WAIST circumference were measured. The body mass index
(BMI) was calculated as weight (kg)/(height (m)2).BMI 90th centile as
per CDC chart was taken as abnormal. Blood pressure was measured on
the right arm of the patient. Presence of family history of diabetes, car-
diovascular diseases and hypercholesterolemia were taken. Fasting Blood
sugar, insulin, HbA1C, lipid proﬁle were done. We used IDF (International
diabetes federation) criteria to assess the metabolic syndrome among
cancer survivors. This study was approved by our university ethics
comittee.
Results: Seventy ﬁve children who fulﬁlled the inclusion criteria were
included in this study. Out of which 48 were males and 27 were females.
Among these, majority of children are treated for acute lymphoblastic
leukemia. 8.25% of total population satisﬁed the criteria of metabolic
syndrome. Age, gender, diagnosis, modality of treatment were not to be of
statistical signiﬁcance, however majority of children with metabolic syn-
drome are in adolescent group.
Conclusion:With the better care committed to childrenwith cancer even in
developing country, the survival rates are greatly improving and so meta-
bolic syndrome is becoming the major target for intervention in the follow
up of cancer survivors. As metabolic syndrome cannot treated by a single
drug therapy, it is necessary to have cancer survivors follow up screening.
